Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma

the Working Group for Genitourinary Tumors

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Long-term oncological outcomes for primary renal cell carcinoma (RCC) treated with carbon-ion radiotherapy (CIRT) are poorly understood. Patients with primary RCC were treated with 12 or 16-fraction CIRT at The Hospital of the National Institute of Radiological Sciences outside of clinical trials. Outcome data were pooled and retrospectively analyzed for toxicity, local control, and disease-free, cancer-specific, and overall survival. From 1997 to 2014, 19 RCC patients (11 with T1aN0M0, 4 with T1bN0M0, and 4 with inoperable advanced stage [T4N0M0, T3aN1M0, and T1aN0M1]) were treated with CIRT and followed up for a median of 6.6 (range, 0.7-16.5) years; 9 of these patients were inoperable because of comorbidities or advanced-stage disease. Diagnoses were confirmed by imaging in 11 patients and by biopsy in the remaining 8. In 4 of 5 patients with definitive renal comorbidities, including diabetic nephropathy, sclerotic kidney or solitary kidney pre-CIRT progressed to grade 4 chronic kidney disease (CKD). In contrast, the remaining 14 patients without definitive renal comorbidities did not progress to grade 3 or higher CKD. Furthermore, although 1 case of grade 4 dermatitis was observed, there were no other grade 3 or higher non-renal adverse events. Local control rate, and disease-free, cancer-specific, and overall survival rates at 5 years of all 19 patients were 94.1%, 68.9%, 100%, and 89.2%, respectively. This updated retrospective analysis based on long-term follow-up data suggests that CIRT is a safe treatment for primary RCC patients without definitive renal comorbidities pre-CIRT, and yield favorable treatment outcomes, even in inoperable cases.

Original languageEnglish
Pages (from-to)2873-2880
Number of pages8
JournalCancer Science
Volume109
Issue number9
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Heavy Ion Radiotherapy
Renal Cell Carcinoma
Comorbidity
Kidney
Chronic Renal Insufficiency
Diabetic Nephropathies
Dermatitis
Neoplasms
Survival Rate
Clinical Trials
Biopsy

Keywords

  • adverse event
  • carbon-ion radiotherapy
  • local control
  • renal cell carcinoma
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma. / the Working Group for Genitourinary Tumors.

In: Cancer Science, Vol. 109, No. 9, 01.09.2018, p. 2873-2880.

Research output: Contribution to journalArticle

the Working Group for Genitourinary Tumors. / Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma. In: Cancer Science. 2018 ; Vol. 109, No. 9. pp. 2873-2880.
@article{437a777d77a846ab8f6dac3660aa32b8,
title = "Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma",
abstract = "Long-term oncological outcomes for primary renal cell carcinoma (RCC) treated with carbon-ion radiotherapy (CIRT) are poorly understood. Patients with primary RCC were treated with 12 or 16-fraction CIRT at The Hospital of the National Institute of Radiological Sciences outside of clinical trials. Outcome data were pooled and retrospectively analyzed for toxicity, local control, and disease-free, cancer-specific, and overall survival. From 1997 to 2014, 19 RCC patients (11 with T1aN0M0, 4 with T1bN0M0, and 4 with inoperable advanced stage [T4N0M0, T3aN1M0, and T1aN0M1]) were treated with CIRT and followed up for a median of 6.6 (range, 0.7-16.5) years; 9 of these patients were inoperable because of comorbidities or advanced-stage disease. Diagnoses were confirmed by imaging in 11 patients and by biopsy in the remaining 8. In 4 of 5 patients with definitive renal comorbidities, including diabetic nephropathy, sclerotic kidney or solitary kidney pre-CIRT progressed to grade 4 chronic kidney disease (CKD). In contrast, the remaining 14 patients without definitive renal comorbidities did not progress to grade 3 or higher CKD. Furthermore, although 1 case of grade 4 dermatitis was observed, there were no other grade 3 or higher non-renal adverse events. Local control rate, and disease-free, cancer-specific, and overall survival rates at 5 years of all 19 patients were 94.1{\%}, 68.9{\%}, 100{\%}, and 89.2{\%}, respectively. This updated retrospective analysis based on long-term follow-up data suggests that CIRT is a safe treatment for primary RCC patients without definitive renal comorbidities pre-CIRT, and yield favorable treatment outcomes, even in inoperable cases.",
keywords = "adverse event, carbon-ion radiotherapy, local control, renal cell carcinoma, survival",
author = "{the Working Group for Genitourinary Tumors} and Goro Kasuya and Hiroshi Tsuji and Takuma Nomiya and Hirokazu Makishima and Yasuo Haruyama and Gen Kobashi and Ebner, {Daniel K.} and Kazuhiko Hayashi and Tokuhiko Omatsu and Riwa Kishimoto and Shigeo Yasuda and Tatsuo Igarashi and Mototsugu Oya and Koichiro Akakura and Hiroyoshi Suzuki and Tomohiko Ichikawa and Jun Shimazaki and Tadashi Kamada",
year = "2018",
month = "9",
day = "1",
doi = "10.1111/cas.13727",
language = "English",
volume = "109",
pages = "2873--2880",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma

AU - the Working Group for Genitourinary Tumors

AU - Kasuya, Goro

AU - Tsuji, Hiroshi

AU - Nomiya, Takuma

AU - Makishima, Hirokazu

AU - Haruyama, Yasuo

AU - Kobashi, Gen

AU - Ebner, Daniel K.

AU - Hayashi, Kazuhiko

AU - Omatsu, Tokuhiko

AU - Kishimoto, Riwa

AU - Yasuda, Shigeo

AU - Igarashi, Tatsuo

AU - Oya, Mototsugu

AU - Akakura, Koichiro

AU - Suzuki, Hiroyoshi

AU - Ichikawa, Tomohiko

AU - Shimazaki, Jun

AU - Kamada, Tadashi

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Long-term oncological outcomes for primary renal cell carcinoma (RCC) treated with carbon-ion radiotherapy (CIRT) are poorly understood. Patients with primary RCC were treated with 12 or 16-fraction CIRT at The Hospital of the National Institute of Radiological Sciences outside of clinical trials. Outcome data were pooled and retrospectively analyzed for toxicity, local control, and disease-free, cancer-specific, and overall survival. From 1997 to 2014, 19 RCC patients (11 with T1aN0M0, 4 with T1bN0M0, and 4 with inoperable advanced stage [T4N0M0, T3aN1M0, and T1aN0M1]) were treated with CIRT and followed up for a median of 6.6 (range, 0.7-16.5) years; 9 of these patients were inoperable because of comorbidities or advanced-stage disease. Diagnoses were confirmed by imaging in 11 patients and by biopsy in the remaining 8. In 4 of 5 patients with definitive renal comorbidities, including diabetic nephropathy, sclerotic kidney or solitary kidney pre-CIRT progressed to grade 4 chronic kidney disease (CKD). In contrast, the remaining 14 patients without definitive renal comorbidities did not progress to grade 3 or higher CKD. Furthermore, although 1 case of grade 4 dermatitis was observed, there were no other grade 3 or higher non-renal adverse events. Local control rate, and disease-free, cancer-specific, and overall survival rates at 5 years of all 19 patients were 94.1%, 68.9%, 100%, and 89.2%, respectively. This updated retrospective analysis based on long-term follow-up data suggests that CIRT is a safe treatment for primary RCC patients without definitive renal comorbidities pre-CIRT, and yield favorable treatment outcomes, even in inoperable cases.

AB - Long-term oncological outcomes for primary renal cell carcinoma (RCC) treated with carbon-ion radiotherapy (CIRT) are poorly understood. Patients with primary RCC were treated with 12 or 16-fraction CIRT at The Hospital of the National Institute of Radiological Sciences outside of clinical trials. Outcome data were pooled and retrospectively analyzed for toxicity, local control, and disease-free, cancer-specific, and overall survival. From 1997 to 2014, 19 RCC patients (11 with T1aN0M0, 4 with T1bN0M0, and 4 with inoperable advanced stage [T4N0M0, T3aN1M0, and T1aN0M1]) were treated with CIRT and followed up for a median of 6.6 (range, 0.7-16.5) years; 9 of these patients were inoperable because of comorbidities or advanced-stage disease. Diagnoses were confirmed by imaging in 11 patients and by biopsy in the remaining 8. In 4 of 5 patients with definitive renal comorbidities, including diabetic nephropathy, sclerotic kidney or solitary kidney pre-CIRT progressed to grade 4 chronic kidney disease (CKD). In contrast, the remaining 14 patients without definitive renal comorbidities did not progress to grade 3 or higher CKD. Furthermore, although 1 case of grade 4 dermatitis was observed, there were no other grade 3 or higher non-renal adverse events. Local control rate, and disease-free, cancer-specific, and overall survival rates at 5 years of all 19 patients were 94.1%, 68.9%, 100%, and 89.2%, respectively. This updated retrospective analysis based on long-term follow-up data suggests that CIRT is a safe treatment for primary RCC patients without definitive renal comorbidities pre-CIRT, and yield favorable treatment outcomes, even in inoperable cases.

KW - adverse event

KW - carbon-ion radiotherapy

KW - local control

KW - renal cell carcinoma

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85052804060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052804060&partnerID=8YFLogxK

U2 - 10.1111/cas.13727

DO - 10.1111/cas.13727

M3 - Article

C2 - 29981249

AN - SCOPUS:85052804060

VL - 109

SP - 2873

EP - 2880

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 9

ER -